A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome

What Was Tested

This randomized controlled trial paper looks at Somatostatin and Pasireotide.

The researchers evaluated the effect of pasireotide, a novel SA with high affinity for 4/5 human somatostatin receptors, on pathophysiological events and symptoms in dumping.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

Randomized double-blind placebo-controlled cross-over study of nine patients (six women, 47 ± 4 years) with postoperative dumping.

Baseline measurements included oral glucose tolerance testing (OGTT), abdominal ultrasound, and dumping symptom severity score (DSSS).

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled, crossover and pilot study.

Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Somatostatin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Somatostatin group a baseline to be compared against.

Each person switched between Somatostatin and the comparison at some point, usually with a gap in between.

On day 13 and 14 of each treatment OGTT, DSSS, and solid and liquid gastric emptying (GE) were obtained.

What Was Measured

The researchers evaluated the effect of pasireotide, a novel SA with high affinity for 4/5 human somatostatin receptors, on pathophysiological events and symptoms in dumping.

The subject headings attached to it are Abdomen, Dumping Syndrome, Hormones, Pilot Projects, Postoperative Complications and Somatostatin.

The authors tagged it with the keywords gastric emptying, glucose tolerance testing, pasireotide, randomized-controlled trial and somatostatin analog.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Somatostatin and Pasireotide.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Neurogastroenterology and motility), a journal based in England.

More context: the Somatostatin compound page and the Pasireotide compound page, all human trials.